Alloimmunization to platelet antigens.
Alloantibodies to platelet-specific antigens can cause significant thrombocytopenia and bleeding in NATP and PTP. IVIG plays an important role in the therapeutic regimen of both of these disorders. Alloantibodies in the multiply transfused patient bind to HLA class I and platelet-specific antigens. IVIG has not improved response to random-donor platelets in refractory patients, but there may be a role for IVIG in critically ill and bleeding patients, in combination with HLA-matched platelets.